<VariationArchive VariationID="194787" VariationName="NM_024312.5(GNPTAB):c.3326dup (p.Asn1109fs)" VariationType="Duplication" Accession="VCV000194787" Version="11" RecordType="classified" NumberOfSubmissions="3" NumberOfSubmitters="3" DateLastUpdated="2024-07-23" DateCreated="2015-06-28" MostRecentSubmission="2024-07-15">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="191950" VariationID="194787">
      <GeneList>
        <Gene Symbol="GNPTAB" FullName="N-acetylglucosamine-1-phosphate transferase subunits alpha and beta" GeneID="79158" HGNC_ID="HGNC:29670" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>12q23.2</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="12" Accession="NC_000012.12" start="101745499" stop="101830959" display_start="101745499" display_stop="101830959" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="12" Accession="NC_000012.11" start="102139274" stop="102224644" display_start="102139274" display_stop="102224644" Strand="-" />
          </Location>
          <OMIM>607840</OMIM>
        </Gene>
      </GeneList>
      <Name>NM_024312.5(GNPTAB):c.3326dup (p.Asn1109fs)</Name>
      <CanonicalSPDI>NC_000012.12:101757580:TTTTT:TTTTTT</CanonicalSPDI>
      <VariantType>Duplication</VariantType>
      <Location>
        <CytogeneticLocation>12q23.2</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="12" Accession="NC_000012.12" start="101757580" stop="101757581" display_start="101757580" display_stop="101757581" variantLength="1" positionVCF="101757580" referenceAlleleVCF="G" alternateAlleleVCF="GT" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="12" Accession="NC_000012.11" start="102151358" stop="102151359" display_start="102151358" display_stop="102151359" variantLength="1" positionVCF="102151358" referenceAlleleVCF="G" alternateAlleleVCF="GT" />
      </Location>
      <ProteinChange>N1109fs</ProteinChange>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000012.11" sequenceAccession="NC_000012" sequenceVersion="11" change="g.102151363dup" Assembly="GRCh37">
            <Expression>NC_000012.11:g.102151363dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000012.12" sequenceAccession="NC_000012" sequenceVersion="12" change="g.101757585dup" Assembly="GRCh38">
            <Expression>NC_000012.12:g.101757585dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_021243.1" sequenceAccession="NG_021243" sequenceVersion="1" change="g.78287dup">
            <Expression>NG_021243.1:g.78287dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_024312.5" sequenceAccession="NM_024312" sequenceVersion="5" change="c.3326dup" MANESelect="true">
            <Expression>NM_024312.5:c.3326dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_077288.2" sequenceAccession="NP_077288" sequenceVersion="2" change="p.Asn1109fs">
            <Expression>NP_077288.2:p.Asn1109fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_024312.5" sequenceAccession="NM_024312" sequenceVersion="5" change="c.3326dupA" MANESelect="true">
            <Expression>NM_024312.5:c.3326dupA</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef ID="CA275048" DB="ClinGen" />
        <XRef Type="rs" ID="797044663" DB="dbSNP" />
      </XRefList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_024312.5(GNPTAB):c.3326dup (p.Asn1109fs) AND not provided" Accession="RCV000175232" Version="4">
        <ClassifiedConditionList TraitSetID="9460">
          <ClassifiedCondition DB="MedGen" ID="C3661900">not provided</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2014-05-20" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_024312.5(GNPTAB):c.3326dup (p.Asn1109fs) AND multiple conditions" Accession="RCV001052463" Version="5">
        <ClassifiedConditionList TraitSetID="9397">
          <ClassifiedCondition DB="MedGen" ID="C2673377">Mucolipidosis type II</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C0033788">Pseudo-Hurler polydystrophy</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2023-09-15" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_024312.5(GNPTAB):c.3326dup (p.Asn1109fs) AND Mucolipidosis" Accession="RCV004586593" Version="1">
        <ClassifiedConditionList TraitSetID="47419">
          <ClassifiedCondition DB="MedGen" ID="C0026697">Mucolipidosis</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2024-04-22" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2024-04-22" NumberOfSubmissions="3" NumberOfSubmitters="3" DateCreated="2015-06-28" MostRecentSubmission="2024-07-15">
        <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">19617216</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">25107912</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="9397" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="3038" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">ML II ALPHA/BETA</ElementValue>
                <XRef Type="MIM" ID="252500" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Mucolipidosis type II</ElementValue>
                <XRef ID="MONDO:0009650" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">I cell disease</ElementValue>
                <XRef ID="Mucolipidosis+II/3706" DB="Genetic Alliance" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Mucolipidosis 2</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">ML 2</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Inclusion cell disease</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Leroy Disease</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">N-acetylglucosamine 1phosphotransferase deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">ML disorder type 2</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">GNPTA</ElementValue>
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">ICD</ElementValue>
                <XRef Type="MIM" ID="252500" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">ML II</ElementValue>
                <XRef Type="MIM" ID="252500" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">GNPTAB-related disorders comprise the phenotypes mucolipidosis II (ML II) and mucolipidosis IIIα/β (ML IIIα/β), and phenotypes intermediate between ML II and ML IIIα/β. ML II is evident at birth and slowly progressive; death most often occurs in early childhood. Orthopedic abnormalities present at birth may include thoracic deformity, kyphosis, clubfeet, deformed long bones, and/or dislocation of the hip(s). Growth often ceases in the second year of life; contractures develop in all large joints. The skin is thickened, facial features are coarse, and gingiva are hypertrophic. All children have cardiac involvement, most commonly thickening and insufficiency of the mitral valve and, less frequently, the aortic valve. Progressive mucosal thickening narrows the airways, and gradual stiffening of the thoracic cage contributes to respiratory insufficiency, the most common cause of death. ML IIIα/β becomes evident at about age three years with slow growth rate and short stature; joint stiffness and pain initially in the shoulders, hips, and fingers; gradual mild coarsening of facial features; and normal to mildly impaired cognitive development. Pain from osteoporosis becomes more severe during adolescence. Cardiorespiratory complications (restrictive lung disease, thickening and insufficiency of the mitral and aortic valves, left and/or right ventricular hypertrophy) are common causes of death, typically in early to middle adulthood. Phenotypes intermediate between ML II and ML IIIα/β are characterized by physical growth in infancy that resembles that of ML II and neuromotor and speech development that resemble that of ML IIIα/β.</Attribute>
                <XRef ID="NBK1828" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">Neoplasm</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">GNPTAB-Related Mucolipidoses</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="6749" />
                <XRef ID="6749" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301728</ID>
                <ID Source="BookShelf">NBK1828</ID>
              </Citation>
              <XRef ID="576" DB="Orphanet" />
              <XRef ID="C2673377" DB="MedGen" />
              <XRef ID="MONDO:0009650" DB="MONDO" />
              <XRef Type="MIM" ID="252500" DB="OMIM" />
            </Trait>
            <Trait ID="3039" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">ML III</ElementValue>
                <XRef Type="MIM" ID="252600" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">ML III ALPHA/BETA</ElementValue>
                <XRef Type="MIM" ID="252600" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Type III Mucolipidosis</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">ML IIIA</ElementValue>
                <XRef Type="MIM" ID="252600" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Mucolipidosis type 3A</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Mucolipidosis III Alpha/Beta</ElementValue>
                <XRef ID="NBK1875" DB="GeneReviews" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">ML 3 A</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Pseudo-Hurler polydystrophy</ElementValue>
                <XRef ID="Mucolipidosis+type+3A/4909" DB="Genetic Alliance" />
                <XRef ID="65764006" DB="SNOMED CT" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">ML3</ElementValue>
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">GNPTAB-related disorders comprise the phenotypes mucolipidosis II (ML II) and mucolipidosis IIIα/β (ML IIIα/β), and phenotypes intermediate between ML II and ML IIIα/β. ML II is evident at birth and slowly progressive; death most often occurs in early childhood. Orthopedic abnormalities present at birth may include thoracic deformity, kyphosis, clubfeet, deformed long bones, and/or dislocation of the hip(s). Growth often ceases in the second year of life; contractures develop in all large joints. The skin is thickened, facial features are coarse, and gingiva are hypertrophic. All children have cardiac involvement, most commonly thickening and insufficiency of the mitral valve and, less frequently, the aortic valve. Progressive mucosal thickening narrows the airways, and gradual stiffening of the thoracic cage contributes to respiratory insufficiency, the most common cause of death. ML IIIα/β becomes evident at about age three years with slow growth rate and short stature; joint stiffness and pain initially in the shoulders, hips, and fingers; gradual mild coarsening of facial features; and normal to mildly impaired cognitive development. Pain from osteoporosis becomes more severe during adolescence. Cardiorespiratory complications (restrictive lung disease, thickening and insufficiency of the mitral and aortic valves, left and/or right ventricular hypertrophy) are common causes of death, typically in early to middle adulthood. Phenotypes intermediate between ML II and ML IIIα/β are characterized by physical growth in infancy that resembles that of ML II and neuromotor and speech development that resemble that of ML IIIα/β.</Attribute>
                <XRef ID="NBK1828" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="3806" />
                <XRef ID="3806" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">GNPTAB-Related Mucolipidoses</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="17704" />
                <XRef ID="17704" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301728</ID>
                <ID Source="BookShelf">NBK1828</ID>
              </Citation>
              <XRef ID="423461" DB="Orphanet" />
              <XRef ID="577" DB="Orphanet" />
              <XRef ID="C0033788" DB="MedGen" />
              <XRef ID="MONDO:0018931" DB="MONDO" />
              <XRef Type="MIM" ID="252600" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="47419" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="9532" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Mucolipidoses</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Mucolipidosis</ElementValue>
                <XRef ID="MONDO:0019248" DB="MONDO" />
                <XRef ID="70528007" DB="SNOMED CT" />
              </Name>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="18975" />
                <XRef ID="18975" DB="Office of Rare Diseases" />
              </AttributeSet>
              <XRef ID="79212" DB="Orphanet" />
              <XRef ID="C0026697" DB="MedGen" />
              <XRef ID="MONDO:0019248" DB="MONDO" />
            </Trait>
          </TraitSet>
          <TraitSet ID="9460" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="17556" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">none provided</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">not provided</ElementValue>
                <XRef ID="13DG0619" DB="Department Of Translational Genomics (developmental Genetics Section), King Faisal Specialist Hospital &amp; Research Centre" />
              </Name>
              <AttributeSet>
                <Attribute Type="public definition">The term 'not provided' is registered in MedGen to support identification of submissions to ClinVar for which no condition was named when assessing the variant. 'not provided' differs from 'not specified', which is used when a variant is asserted to be benign, likely benign, or of uncertain significance for conditions that have not been specified.</Attribute>
              </AttributeSet>
              <XRef ID="C3661900" DB="MedGen" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="414993" SubmissionDate="2016-11-03" DateLastUpdated="2015-06-28" DateCreated="2015-06-28">
        <ClinVarSubmissionID localKey="20005_000000" localKeyIsSubmitted="1" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000226678" DateUpdated="2015-06-28" DateCreated="2015-06-28" Type="SCV" Version="4" SubmitterName="Eurofins Ntd Llc (ga)" OrgID="500060" OrganizationCategory="laboratory" OrgAbbreviation="EGL" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2014-05-20">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">EGL Classification Definitions</Attribute>
          <Citation Type="general">
            <URL>http://www.egl-eurofins.com/emvclass/EGLClassificationDefinitions.php</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
              <Gender>mixed</Gender>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="VariantAlleles" integerValue="1" />
            </ObservedData>
            <ObservedData>
              <Attribute Type="SingleHeterozygote" integerValue="1" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GNPTAB" />
          </GeneList>
          <VariantType>Duplication</VariantType>
          <Location>
            <SequenceLocation Assembly="GRCh37" Chr="12" alternateAllele="T" referenceAllele="-" start="102151358" stop="102151359" variantLength="2" />
            <GeneLocation>NM_024312.4:Ex17</GeneLocation>
          </Location>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">not provided</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <Citation>
          <URL>http://geneticslab.emory.edu/emvclass/emvclass.php?approved_symbol=GNPTAB</URL>
        </Citation>
        <SubmissionNameList>
          <SubmissionName>EGL003</SubmissionName>
          <SubmissionName>EGL004</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="9856248" SubmissionDate="2024-07-09" DateLastUpdated="2024-07-15" DateCreated="2024-07-15">
        <ClinVarSubmissionID localKey="NM_024312.5:c.3326dupA|MedGen:C0026697" />
        <ClinVarAccession Accession="SCV005077026" DateUpdated="2024-07-15" DateCreated="2024-07-15" Type="SCV" Version="1" SubmitterName="Women's Health and Genetics/Laboratory Corporation of America, LabCorp" OrgID="500026" OrganizationCategory="laboratory" OrgAbbreviation="WHG-LC" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2024-04-22">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>Variant summary: GNPTAB c.3326dupA (p.Asn1109LysfsX4) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. The variant was absent in 251250 control chromosomes (gnomAD). To our knowledge, no occurrence of c.3326dupA in individuals affected with Mucolipidosis and no experimental evidence demonstrating its impact on protein function have been reported. ClinVar contains an entry for this variant (Variation ID: 194787). Based on the evidence outlined above, the variant was classified as pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">LabCorp Variant Classification Summary - May 2015</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/rtxspsnt/labcorp_variant_classification_method_-_may_2015.pdf</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GNPTAB" />
          </GeneList>
          <VariantType>Duplication</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_024312.5:c.3326dupA</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0026697" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>clinvar-submission.2024-04.revised.csv</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="2382087" SubmissionDate="2024-02-15" DateLastUpdated="2024-02-28" DateCreated="2020-04-15">
        <ClinVarSubmissionID localKey="6363038|MedGen:C0033788;C2673377" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001216675" DateUpdated="2024-02-28" DateCreated="2020-04-15" Type="SCV" Version="5" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-09-15">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">19617216</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">25107912</ID>
          </Citation>
          <Comment>This sequence change creates a premature translational stop signal (p.Asn1109Lysfs*4) in the GNPTAB gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in GNPTAB are known to be pathogenic (PMID: 19617216, 25107912). This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with GNPTAB-related conditions. ClinVar contains an entry for this variant (Variation ID: 194787). For these reasons, this variant has been classified as Pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GNPTAB" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000012.11:g.102151358_102151359insT</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease" multipleConditionExplanation="Uncertain">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0033788" Type="CUI" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C2673377" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB11431369</SubmissionName>
          <SubmissionName>SUB12508014</SubmissionName>
          <SubmissionName>SUB14224806</SubmissionName>
          <SubmissionName>SUB8755776</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="9856248" TraitType="Disease" MappingType="XRef" MappingValue="C0026697" MappingRef="MedGen">
        <MedGen CUI="C0026697" Name="Mucolipidosis" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2382087" TraitType="Disease" MappingType="XRef" MappingValue="C0033788" MappingRef="MedGen">
        <MedGen CUI="C0033788" Name="Pseudo-Hurler polydystrophy" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2382087" TraitType="Disease" MappingType="XRef" MappingValue="C2673377" MappingRef="MedGen">
        <MedGen CUI="C2673377" Name="Mucolipidosis type II" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="414993" TraitType="Disease" MappingType="Name" MappingValue="not provided" MappingRef="Preferred">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

